Biopharmaceutical company Bristol-Myers Squibb Co. reported Tuesday a profit for the first quarter that grew from last year, boosted by increased sales of core drugs, particularly its new melanoma treatment Yervoy. Both adjusted earnings per share and quarterly revenues topped analysts’ expectations. The company also raised earnings guidance for the full-year 2015.